Table 7.
Laboratory findings before and after ezetimibe treatments in women
| Baseline | 24 weeks | P-value (95% CI) | |
|---|---|---|---|
| AST (IU/L) | 21.9 ± 6.6 | 28.8 ± 25.9 | 0.128 |
| ALT (IU/L) | 22.6 ± 10.5 | 25.4 ± 17.2 | 0.269 |
| γ-GTP (IU/L) | 27.6 ± 23.5 | 25.0 ± 16.0 | 0.348 |
| CPK (IU/L) | 124.5 ± 52.0 | 118.4 ± 68.4 | 0.376 |
| BUN (mg/dL) | 17.3 ± 5.0 | 17.7 ± 6.3 | 0.413 |
| Creatinine (mg/dL) | 0.67 ± 0.19 | 0.63 ± 0.15 | 0.232 |
| Uric acid (mg/dL) | 5.11 ± 1.57 | 4.93 ± 1.69 | 0.365 |
| Triglycerides (mg/dL)* | 149.9 (64–371) | 108.9 (54–443) | 0.038 (−4.19 to 90.71) |
| HDL-cholesterol (mg/dL) | 57.4 ± 18.6 | 58.9 ± 19.6 | 0.403 |
| Non HDL-cholesterol (mg/dL) | 159.8 ± 43.7 | 128.2 ± 27.4 | 0.005 |
| LDL-cholesterol (mg/dL) | 136.8 ± 35.1 | 105.1 ± 26.4 | 0.001 |
| Fasting plasma glucose (mg/dL) | 100.4 ± 14.7 | 111.4 + 31.2 | 0.081 |
| Hemoglobin Alc (%) | 5.7 ± 0.4 | 5.6 ± 1.0 | 0.340 |
| Insulin (μU/mL)* | 11.8 (2.6–49.9) | 9.2 (3.5–110) | 0.140 (−4.59 to 9.41) |
| HOMA-IR* | 3.01 (0.7–10.2) | 2.11 (0.87–7.22) | 0.047 (−1.14–1.84) |
| White blood cell count (×102/mm3) | 5628 ± 1316 | 5213 ± 1444 | 0.174 |
| Hemoglobin (g/dL) | 13.1 ± 1.0 | 13.0 ± 1.0 | 0.377 |
| Platelet (×104/mm3) | 23.7 ± 6.1 | 22.9 ± 6.5 | 0.345 |
| High sensitivity CRP (mg/dL)* | 0.14 (0.023–0.194) | 0.13 (0.014–0.495) | 0.356 (−0.07 to 0.39) |
| RLP-c (mg/dL)* | 7.12 (2.1–14.7) | 7.47 (1.9–22.3) | 0.421 (−4.11 to 5.87) |
| Free fatty acid (mEq/L) | 0.58 ± 0.29 | 0.49 ± 0.23 | 0.142 |
*
Data are means ± standard deviation, geometric mean and range. These variables are shown in the original scale after analysis using log (natural)-transformed values.
γ-GTP, γ-glutamyl transpeptidase; ALT, alanine aminotransferase; AST, asparatate aminotransferase; BUN, blood urea nitrogen; CI, confidence interval; CPK, creatine phosphokinase; CRP, C-reactive protein; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; RLP-c, remnant-like particle cholesterol.